BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the first patient treated under an Investigational Device Exemption, aiming to secure FDA Premarket Approval for its GalaFLEX LITE Scaffold. The trial focuses on evaluating the scaffold's ability to reduce the recurrence of capsular contracture (“CC”) in breast revision surgeries.By advancing this innovative solution, BD is working to address unmet needs in breast reconstruction procedures. The trial reflects the company’s commi ...